REHOVOT, Israel, March 15,
2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage
biopharmaceutical company developing innovative microbiome-based
therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE:
EVGN), today announced that its VP R&D, Dr. Shiri Meshner, will
be presenting at the Pharmabiotics 2023 Conference, 'The Future of Microbiome-based
Medicines', taking place in
Lyon, France from March 21-22, 2023.
Dr. Meshner will be presenting on March
21, at 3:40pm CET, in a
presentation entitled, 'Biomica's BMC128 - a Rationally Designed
LBP Consortium's Journey to the Clinic.'
Biomica's proprietary BMC128 is a rationally designed consortia
of 4 live bacterial strains which demonstrated a significant
reduction of cancer tumor volumes and increased survival in
pre-clinical animal studies compared to anti-PD1 therapy alone.
BMC128 is currently being tested in a 12 patient Phase 1 open
label study (ClinicalTrials.gov Identifier: NCT05354102) to
primarily evaluate its safety and tolerability in combination with
anti-PD-1 (Opdivo) in patients with either non-small cell lung
cancer (NSCLC), melanoma or renal cell carcinoma (RCC), in patients
whose cancers did not respond to treatment with an anti-PD-1 drug.
The objectives in this Phase 1 trial will also explore efficacy
variables.
Dr. Meshner will be available for one-on-one meetings with
participants throughout the conference, and those interested should
be in touch with her directly.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing MicroBoost
AI tech-engine, licensed from Evogene. Biomica aims to
identify and characterize disease-related microbiome entities and
to develop novel therapeutics based on these understandings. The
company is focused on the development of therapies for antibiotic
resistant bacteria, immuno-oncology, and microbiome-related
gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene
Ltd. (NASDAQ: EVGN) (TASE: EVGN).
For more information about Biomica, please visit
www.biomicamed.com.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
Investor Contact:
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040
Dr. Shiri Meshner, PhD, VP of R&D
Email: shiri.meshner@biomicamed.com
Logo:
https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-vp-rd-to-present-at-the-pharmabiotics-2023-conference-on-march-21-2023-301772684.html
SOURCE Biomica Ltd.